These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 30047799)

  • 61. Interferon-free therapies for patients with chronic hepatitis C genotype 3 infection: A systematic review.
    Gimeno-Ballester V; Buti M; San Miguel R; Riveiro M; Esteban R
    J Viral Hepat; 2017 Nov; 24(11):904-916. PubMed ID: 27925386
    [TBL] [Abstract][Full Text] [Related]  

  • 62. The influence of immunosuppressants on direct-acting antiviral therapy is dependent on the hepatitis C virus genotype.
    Frey A; Piras-Straub K; Walker A; Timm J; Gerken G; Herzer K
    Transpl Infect Dis; 2018 Feb; 20(1):. PubMed ID: 29111569
    [TBL] [Abstract][Full Text] [Related]  

  • 63. [Association between ribavirin plasma concentration and sustained virologic response in treatment of patients with genotype 1b chronic hepatitis C with pegylated interferon-α-2b and ribavirin].
    Wang MR; Zhang X; Yang ZG; Li P; Gao L; Chen XH; Wang J; Xiong X; Wang SM; Geng JB; Hao KY; Xie F; Wang M; Zheng WK
    Zhonghua Gan Zang Bing Za Zhi; 2016 Mar; 24(3):175-80. PubMed ID: 27095759
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Hyperinsulinaemia reduces the 24-h virological response to PEG-interferon therapy in patients with chronic hepatitis C and insulin resistance.
    Bortoletto G; Scribano L; Realdon S; Marcolongo M; Mirandola S; Franceschini L; Bonisegna S; Noventa F; Plebani M; Martines D; Alberti A
    J Viral Hepat; 2010 Jul; 17(7):475-80. PubMed ID: 19878535
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Review: In chronic hepatitis C virus infection, oral direct-acting antivirals have high sustained virologic response.
    Sacks HS
    Ann Intern Med; 2017 Jul; 167(2):JC3. PubMed ID: 28715825
    [No Abstract]   [Full Text] [Related]  

  • 66. Successful combination of direct antiviral agents in liver-transplanted patients with recurrent hepatitis C virus.
    Rupp C; Hippchen T; Neuberger M; Sauer P; Pfeiffenberger J; Stremmel W; Gotthardt DN; Mehrabi A; Weiss KH
    World J Gastroenterol; 2018 Mar; 24(12):1353-1360. PubMed ID: 29599610
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Dramatic response of hepatitis C patients chronically infected with hepatitis C virus genotype 3 to sofosbuvir-based therapies in Punjab, Pakistan: A prospective study.
    Iqbal S; Yousuf MH; Yousaf MI
    World J Gastroenterol; 2017 Nov; 23(44):7899-7905. PubMed ID: 29209131
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Cardiometabolic effects of direct-acting antivirals in patients with hepatitis C.
    Neokosmidis G; Protopapas AA; Stogiannou D; Filippidis A; Tziomalos K
    Gastroenterol Hepatol; 2023 Jan; 46(1):58-66. PubMed ID: 35460863
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Analysis of Host and Viral-Related Factors Associated to Direct Acting Antiviral Response in Hepatitis C Virus Patients.
    Aziz H; Aziz M; Gill ML
    Viral Immunol; 2018 Apr; 31(3):256-263. PubMed ID: 29664710
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Ribavirin posology, observance, and sustained virologic response.
    Couzigou P; Foucher J; Castera L; De Ledinghen V
    Clin Gastroenterol Hepatol; 2008 Mar; 6(3):367. PubMed ID: 18063421
    [No Abstract]   [Full Text] [Related]  

  • 71. Telaprevir: changing the standard of care of chronic hepatitis C.
    Rajani AK; Ravindra BK; Dkhar SA
    J Postgrad Med; 2013; 59(1):42-7. PubMed ID: 23525057
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Impact of treatment with direct-acting antivirals on anxiety and depression in chronic hepatitis C.
    Gallach M; Vergara M; da Costa JP; Miquel M; Casas M; Sanchez-Delgado J; Dalmau B; Rudi N; Parra I; Monllor T; Sanchez-Lloansí M; Dosal A; Valero O; Calvet X
    PLoS One; 2018; 13(12):e0208112. PubMed ID: 30566421
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Safety and effectiveness of direct acting antivirals for treatment of hepatitis C virus in patients with solid organ transplantation.
    Mansour M; Hill L; Kerr J
    Transpl Infect Dis; 2018 Dec; 20(6):e12972. PubMed ID: 30080955
    [TBL] [Abstract][Full Text] [Related]  

  • 74. The risk of hepatocellular carcinoma after sustained virological response in patients treated with the new direct-acting antiviral drugs: should we be worry about it?
    Blanco JR; Rivero-Juárez A
    Expert Rev Anti Infect Ther; 2016 Nov; 14(11):993-996. PubMed ID: 27686837
    [No Abstract]   [Full Text] [Related]  

  • 75. Cost-effectiveness of the highly effective direct-acting antivirals in the treatment of chronic hepatitis C in Hong Kong.
    Lo AO; Chan HL; Wong VW; Wong GL
    J Gastroenterol Hepatol; 2017 May; 32(5):1071-1078. PubMed ID: 28449343
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Hepatitis C in Children and Adolescents of a Brazilian Tertiary Center: Identifying Patients Eligible for Direct-Acting Antivirals.
    Hirsch CB; Pereira MFB; Benevides GN; Bernardes TM; Palandri GG; Bastos KLM; Toma RK; de Azevedo RA; Marques HHS
    Pediatr Infect Dis J; 2020 Sep; 39(9):e276-e278. PubMed ID: 32496409
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Hepatitis C virus drug resistance: implications for clinical management.
    Wyles DL
    Infect Dis Clin North Am; 2012 Dec; 26(4):967-78. PubMed ID: 23083827
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Immunosuppressive and antiviral treatment of hepatitis C virus-associated glomerular disease: A long-term follow-up.
    Fabrizi F; Aghemo A; Lampertico P; Fraquelli M; Cresseri D; Moroni G; Passerini P; Donato FM; Messa P
    Int J Artif Organs; 2018 Jun; 41(6):306-318. PubMed ID: 29595085
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Retreatment with direct-acting antivirals of genotypes 1-3-4 hepatitis C patients who failed an anti-NS5A regimen in real world.
    Halfon P; Scholtès C; Izopet J; Larrat S; Trimoulet P; Zoulim F; Alric L; Métivier S; Leroy V; Ouzan D; de Lédinghen V; Mohamed S; Pénaranda G; Khiri H; Thélu MA; Plauzolles A; Chiche L; Bourlière M; Abravanel F
    J Hepatol; 2018 Mar; 68(3):595-597. PubMed ID: 28987520
    [No Abstract]   [Full Text] [Related]  

  • 80. Insulin resistance and response to telaprevir plus peginterferon α and ribavirin in treatment-naive patients infected with HCV genotype 1.
    Serfaty L; Forns X; Goeser T; Ferenci P; Nevens F; Carosi G; Drenth JP; Lonjon-Domanec I; DeMasi R; Picchio G; Beumont M; Marcellin P
    Gut; 2012 Oct; 61(10):1473-80. PubMed ID: 22387529
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.